Boris Minev
Chief Tech/Sci/R&D Officer bij CALIDI BIOTHERAPEUTICS, INC.
Vermogen: 239 819 $ op 31-03-2024
Profiel
Boris Minev is currently the Chief Medical Officer & President-Medical Affairs at Calidi Biotherapeutics, Inc. He previously worked as the Director-Immunotherapy & Translational Oncology at Genelux Corp.
from 2010 to 2015, and as the Director-Tumor Immunology & Immunotherap at UCSD Moores Cancer Center from 2000 to 2015.
Dr. Minev holds a doctorate degree from Medical University Sofia.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 04-03-2024 | 424 458 ( 1.19% ) | 239 819 $ | 31-03-2024 |
Actieve functies van Boris Minev
| Bedrijven | Functie | Begin |
|---|---|---|
| CALIDI BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Boris Minev
| Bedrijven | Functie | Einde |
|---|---|---|
| GENELUX CORPORATION | Corporate Officer/Principal | 01-06-2015 |
UCSD Moores Cancer Center
 UCSD Moores Cancer Center Miscellaneous Commercial ServicesCommercial Services Part of University of California, UCSD Moores Cancer Center provides clinical and medical research services for cancer treatment. The private company is based in La Jolla, CA. | Corporate Officer/Principal | 01-06-2015 |
Opleiding van Boris Minev
| Medical University Sofia | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GENELUX CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
UCSD Moores Cancer Center
UCSD Moores Cancer Center Miscellaneous Commercial ServicesCommercial Services Part of University of California, UCSD Moores Cancer Center provides clinical and medical research services for cancer treatment. The private company is based in La Jolla, CA. | Commercial Services |
| Calidi Biotherapeutics, Inc. |
